Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Notizie Vai al feed delle notizie

Acumen Pharmaceuticals unveils new Alzheimer strategy with sabirnetug at Citi conference

Acumen Pharmaceuticals presented its approach to treating Alzheimer’s at Citi’s “Biopharma Back to School Conference,” focusing on the antibody sabirnetug against Aβ oligomers, plans for a subcutaneous formulation, and improved brain targeting in collaboration with JCR Pharmaceuticals. The company emphasized use of biomarkers (including pTau217), AI/ML analyses for data processing, reported positive Phase 1 signals, and highlighted the ongoing ALTITUDE‑AD study for further validation. Acumen sees combination therapies as the future and expects a preclinical EBD candidate in early 2026. » Altro su de.investing.com
Acumen Pharmaceuticals misses Q2 forecast and shares slip in premarket

Acumen Pharmaceuticals reported Q2 2025 EPS of -$0.68, missing the estimate of -$0.51, which led to a 1.41% decline in premarket trading. Higher R&D expenses drove the net loss to $41 million; cash and cash equivalents stood at $166.2 million and are expected to last into early 2027. The company reaffirmed its collaboration with JCR Pharmaceuticals and expects top-line data from the Phase 2 ALPITUDE AD study by the end of 2026. » Altro su de.investing.com

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 2026, JCR PHARM. ha già distribuito 0,0544 € di dividendi. L'ultimo pagamento è avvenuto a giugno.

Dati finanziari dell'azienda

Nell'ultimo trimestre, JCR PHARM. ha registrato ricavi pari a 52,26 Mln € e un utile netto di -10,28 Mln €

(EUR)	giugno 2026	YoY
Ricavi	52,26 Mln	3,37%
Utile lordo	40,14 Mln	10,20%
Utile netto	-10,28 Mln	219,11%
EBITDA	-8,54 Mln	2294,36%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	362,58 Mln €
Numero di azioni	122,02 Mln
Massimo/minimo a 52 settimane	4,62 € - 2,49 €
Rendimento da dividendo	3,80%
Dividendi TTM	0,11 €
Beta	0,42
Rapporto P/E	78,87
Rapporto PEG	1,21
Rapporto P/B	1,50
Rapporto P/S	1,56

Profilo aziendale

JCR Pharmaceuticals Co. Ltd. ist ein Spezialpharmaunternehmen, das sich mit der Erforschung, Entwicklung, Herstellung, dem Import und Export sowie dem Verkauf von pharmazeutischen Produkten, regenerativen Arzneimitteln und Drogensubstanzen in Japan beschäftigt. Es bietet verschiedene therapeutische Produkte an, darunter GROWJECT zur Behandlung von Wachstumshormonmangel und Kleinwuchs, IZCARGO zur Behandlung von Mukopolysaccharidose Typ II, Agalsidase Beta BS I.V. Infusion zur Behandlung der Fabry-Krankheit und TEMCELL HS Inj zur Behandlung der akuten Graft-versus-Host-Krankheit. Das Unternehmen entwickelt auch Epoetin Alfa BS und Darbepoetin Alfa BS Injektionen für die Behandlung von renaler Anämie. Darüber hinaus vertreibt das Unternehmen medizinische Geräte und Laborinstrumente. JCR Pharmaceuticals Co., Ltd. wurde 1975 gegründet und hat seinen Hauptsitz in Ashiya, Japan.